Éric Sicard

922 total citations
23 papers, 660 citations indexed

About

Éric Sicard is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, Éric Sicard has authored 23 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Epidemiology. Recurrent topics in Éric Sicard's work include Poisoning and overdose treatments (3 papers), Respiratory and Cough-Related Research (3 papers) and Alcohol Consumption and Health Effects (3 papers). Éric Sicard is often cited by papers focused on Poisoning and overdose treatments (3 papers), Respiratory and Cough-Related Research (3 papers) and Alcohol Consumption and Health Effects (3 papers). Éric Sicard collaborates with scholars based in United States, Spain and Canada. Éric Sicard's co-authors include Wendy Cheng, John G. McHutchison, G. Mani Subramanian, Edward Gane, Richard N. Fedorak, Stephen Ryder, Graham R. Foster, Kosh Agarwal, Tuan Nguyen and Scott Fung and has published in prestigious journals such as Hepatology, Neurology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Éric Sicard

23 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Sicard United States 12 277 226 179 72 59 23 660
Ludmila Vīksna Latvia 14 161 0.6× 113 0.5× 328 1.8× 30 0.4× 62 1.1× 44 639
Estela Monteiro Portugal 15 168 0.6× 105 0.5× 104 0.6× 38 0.5× 149 2.5× 52 668
Recep Keşli Türkiye 12 172 0.6× 97 0.4× 81 0.5× 75 1.0× 79 1.3× 46 560
Joop E. Arends Netherlands 19 644 2.3× 687 3.0× 346 1.9× 78 1.1× 45 0.8× 91 1.1k
Haidi Karam‐Allah Ramadan Egypt 13 73 0.3× 86 0.4× 149 0.8× 26 0.4× 93 1.6× 44 514
Anna D. Grabowska Poland 14 100 0.4× 50 0.2× 202 1.1× 34 0.5× 139 2.4× 42 733
Philip Abraham India 22 369 1.3× 238 1.1× 297 1.7× 44 0.6× 253 4.3× 99 1.6k
Isabelle Ravaux France 17 420 1.5× 201 0.9× 613 3.4× 42 0.6× 143 2.4× 48 1.1k
Sujit Chaudhuri India 16 341 1.2× 303 1.3× 104 0.6× 41 0.6× 71 1.2× 50 868
Francisco Jover Spain 11 170 0.6× 70 0.3× 91 0.5× 9 0.1× 40 0.7× 43 442

Countries citing papers authored by Éric Sicard

Since Specialization
Citations

This map shows the geographic impact of Éric Sicard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Sicard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Sicard more than expected).

Fields of papers citing papers by Éric Sicard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Sicard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Sicard. The network helps show where Éric Sicard may publish in the future.

Co-authorship network of co-authors of Éric Sicard

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Sicard. A scholar is included among the top collaborators of Éric Sicard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Sicard. Éric Sicard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Setnik, Beatrice, et al.. (2021). The bioequivalence of fixed‐dose combination tablets of bisoprolol and ramipril and its drug‐drug interaction potential. Clinical and Translational Science. 15(1). 158–171. 3 indexed citations
2.
Sicard, Éric, Paul Griffin, Lindsey O. Webster, et al.. (2019). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079). Neurology. 92(15_supplement). 25 indexed citations
4.
Kokai‐Kun, John F., Tracey Roberts, Éric Sicard, et al.. (2017). The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies. Antimicrobial Agents and Chemotherapy. 61(3). 57 indexed citations
5.
Sicard, Éric, et al.. (2017). Effect of Alcohol Administered with Flibanserin on Dizziness, Syncope, and Hypotension in Healthy, Premenopausal Women. The Journal of Sexual Medicine. 14(Supplement_4b). e331–e331. 3 indexed citations
6.
Guzmán, Cristina B., Hélène Dulude, Claude A. Piché, et al.. (2017). Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obesity and Metabolism. 20(3). 646–653. 23 indexed citations
7.
Algorta, Jaime, Marc Lefebvre, Éric Sicard, et al.. (2017). Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg). The European Journal of Contraception & Reproductive Health Care. 22(6). 429–438. 27 indexed citations
8.
Videla, Sebastián, Anna Vaqué, Mariano Sust, et al.. (2017). Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects. British Journal of Clinical Pharmacology. 83(12). 2718–2728. 41 indexed citations
9.
Kay, Gary G., et al.. (2017). Next-day residual effects of flibanserin on simulated driving performance in premenopausal women. Human Psychopharmacology Clinical and Experimental. 32(4). e2603–e2603. 22 indexed citations
10.
Videla, Sebastián, Anna Vaqué, Mariano Sust, et al.. (2017). Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial. British Journal of Clinical Pharmacology. 84(1). 64–78. 23 indexed citations
12.
Gane, Edward, Young‐Suk Lim, Stuart C. Gordon, et al.. (2015). The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. Journal of Hepatology. 63(2). 320–328. 149 indexed citations
13.
Agarwal, Kosh, Scott Fung, Tuan Nguyen, et al.. (2014). Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. Journal of Hepatology. 62(3). 533–540. 144 indexed citations
14.
Gane, Edward, Éric Sicard, Stuart C. Gordon, et al.. (2013). Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B. Hepatology. 58. 4 indexed citations
16.
Sicard, Éric, et al.. (2013). A Phase I Assessment of the Safety and Tolerability Profile of Novel Treatments for Acute Allergic Reactions Administered by Intravenous and Intramuscular Injection Formulations. Journal of Allergy and Clinical Immunology. 131(2). AB26–AB26. 1 indexed citations
17.
Videla, Sebastián, et al.. (2012). Food Effects on the Pharmacokinetics of Doxylamine Hydrogen Succinate 25 mg Film-Coated Tablets. Drugs in R&D. 12(4). 217–225. 7 indexed citations
18.
Videla, Sebastián, et al.. (2012). Food Effects on the Pharmacokinetics of Doxylamine Hydrogen Succinate 25 mg Film-Coated Tablets. Drugs in R&D. 12(4). 217–225. 1 indexed citations
20.
Bitzan, Martin, et al.. (2009). Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 53(7). 3081–3087. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026